MIIT: China's Pharmaceutical Industry Innovation Capacity Significantly Enhanced in First Half of Year 工业和信息化部：今年上半年我国医药工业创新能力显著增强

Summary

The MIIT’s first-half press conference revealed that China’s pharmaceutical industry has significantly strengthened its innovation capacity, with 38 innovative drugs approved, over 80% of which were domestically produced.
Transaction volumes for the international licensing of innovative drug technologies exceeded $100 billion, with a batch of "first-in-the-world" achievements receiving centralized approval, reflecting a systematic leap forward.
The MIIT announced plans to accelerate the release of an "AI + Software" action plan, promoting the intelligent transformation of software development and the cultivation of new business formats involving agent-based software.
Efforts will be intensified to strengthen open-source infrastructure construction, enhancing its capabilities in project incubation, supply chain security, and overseas market deployment.

Deep Analysis

TL;DR

• The MIIT’s first-half press conference revealed that China’s pharmaceutical industry has significantly strengthened its innovation capacity, with 38 innovative drugs approved, over 80% of which were domestically produced.
• Transaction volumes for the international licensing of innovative drug technologies exceeded $100 billion, with a batch of "first-in-the-world" achievements receiving centralized approval, reflecting a systematic leap forward.
• The MIIT announced plans to accelerate the release of an "AI + Software" action plan, promoting the intelligent transformation of software development and the cultivation of new business formats involving agent-based software.
• Efforts will be intensified to strengthen open-source infrastructure construction, enhancing its capabilities in project incubation, supply chain security, and overseas market deployment.

Why It Matters

This article highlights dual policy trends in the pharmaceutical and software/AI sectors. It showcases China’s substantive innovation breakthroughs in biomedicine while clarifying the national strategic path for deep integration of AI and software. For professionals focusing on hard technology, biomedicine, and the practical application of AI, this serves as a crucial reference for understanding current industrial policy directions and technological evolution trends.

Technical Analysis

• Pharmaceutical Innovation Data: 38 innovative drugs were approved in the first half of the year, including 31 domestic ones (accounting for >80%), emphasizing "first-in-the-world" achievements, which reflects an improvement in source-level R&D innovation capabilities.
• AI + Software Strategy: The MIIT proposed accelerating the release of an "AI + Software" action plan. The core objective is to promote the intelligent transformation of software development, the intelligent upgrade of products and services, and the cultivation of new business formats involving agent (Agent) software.
• Open-Source Ecosystem Construction: Emphasis is placed on enhancing the capabilities of open-source infrastructure in project incubation, supply chain security governance, exploration of emerging scenarios, and overseas market deployment. The aim is to establish a national-level AI open-source community as a source of innovation.

Industry Implications

• Going Global and License-outs Become the New Normal: Technology licensing transactions exceeding hundreds of billions of dollars indicate that Chinese innovative pharmaceutical companies are shifting from simple product exports to high-value intellectual property output. Original innovations with global competitiveness will become the core barrier for the industry.
• AI Reshaping the Software Engineering Paradigm: The introduction of the "AI + Software" action plan signals that development processes will become fully intelligent. Developers must adapt to new workflows assisted by AI for coding, testing, and deployment, with agent-based software potentially becoming a new competitive frontier.
• Balancing Open-Source Security and Globalization: Policies emphasize the role of open source in supply chain security and overseas deployment. Enterprises should prioritize the establishment of open-source compliance frameworks and leverage open-source communities to accelerate technological iteration and expansion into international markets.

TL;DR

• 工信部上半年发布会显示我国医药工业创新能力显著增强，38款创新药获批其中国产占超80%。
• 创新药对外技术授权交易额超1000亿美元，一批“全球首个”成果集中获批，体现系统性跃升。
• 工信部宣布加快出台“人工智能+软件”行动方案，推动软件开发智能化转型及智能体软件新业态培育。
• 强化开源基础设施建设，提升其在项目孵化、供应链安全及海外市场落地等方面的能力。

为什么值得看

本文揭示了医药产业与软件/AI产业的双重政策动向，既展示了中国在生物医药领域的实质性创新突破，也明确了国家层面推动AI与软件深度融合的战略路径。对于关注硬科技、生物医药及AI应用落地的从业者而言，这是理解当前产业政策风向和技术演进趋势的重要参考。

技术解析

• 医药创新数据：上半年获批38款创新药，其中国产31款（占比>80%），强调“全球首个”成果，反映研发源头创新能力提升。
• AI+软件战略：工信部提出加快出台“人工智能+软件”行动方案，核心目标是推动软件开发智能化转型、产品服务智能化升级以及智能体（Agent）软件新业态的培育。
• 开源生态建设：重点提及提升开源基础设施在项目孵化、供应链安全治理、新兴场景探索及海外市场落地方面的能力，旨在将国家级人工智能开源社区打造为创新策源地。

行业启示

• 医药出海与License-out成为新常态：超千亿美元的技术授权交易表明，中国创新药企正从单纯的产品出口转向高价值的知识产权输出，具备全球竞争力的原始创新将成为行业核心壁垒。
• AI重塑软件工程范式：“AI+软件”行动方案的出台预示着开发流程将全面智能化，开发者需适应由AI辅助编码、测试到部署的新工作流，智能体软件可能成为新的竞争高地。
• 开源安全与全球化并重：政策强调开源在供应链安全和海外落地中的作用，企业应重视开源合规性建设，并利用开源社区加速技术迭代和国际市场拓展。